SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being linked to debt and credit concerns across AI neoclouds, amplified by Elon Musks warning of industry failures and consolidation. Bulls argue IRENs contracts, power access and financing set it apart, while bears worry about capital constraints, execution and further losses.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure as traders react to Elon Musks warning that many neocloud providers may fail or consolidate and his statement that SpaceX will not buy one, intensifying concerns about CRWVs debt-heavy expansion and access to financing. The debate pits fears of insolvency and dilution against bullish arguments that AI demand, backlog, and Nvidia ties can support the company.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that many neocloud providers could fail or consolidate, alongside concerns about tighter credit and debt-funded data-center expansion, has focused attention on NBIS. Bulls argue Nebius is better positioned and that AI-compute demand remains strong, while bears question the sectors financing risks and Nebiuss ability to execute its buildout.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians upcoming quarterly results and guidance are the main focus as the stock trades near recent lows, with traders questioning whether the R2 ramp can improve margins and cash burn. Bearish concerns about execution and persistent losses contrast with bullish arguments citing stronger deliveries and potential progress toward profitability.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFR is caught in a sharp selloff across AI data-center stocks amid worries about tighter financing and Elon Musks warnings about risks to smaller compute-cloud operators. Traders debate whether CIFRs powered-site and long-term lease model makes it less exposed, while the convertible-note offering and potential dilution add pressure; sentiment is split between capitulation and dip-buying ahead of earnings.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention after Lula da Silva defeated Flvio Bolsonaro in Brazils presidential runoff, reversing market positioning that had favored Bolsonaro and prompting a sharp selloff in Brazilian equities. Traders are debating whether the drop reflects heightened political and economic uncertainty or an overreaction that could create a buying opportunity; claims that the result was rigged remain speculation.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is drawing attention after reporting a record quarter with its first-ever quarterly profit above $1 billion and continued strong growth, prompting a sharp rally and bullish reactions. Some traders remain cautious about credit quality and expect volatility or profit-taking after the move.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is caught in a broad AI data-center and neocloud selloff as traders react to Elon Musks warning that tighter debt markets could pressure smaller AI-focused operators, raising concerns about financing for capital-intensive expansion. The community is split between investors citing APLDs contracted capacity and insider purchases as reasons for confidence, and skeptics focused on debt, dilution and whether demand will translate into returns.

Lufax Holding Ltd. operates a technology-empowered personal financial services platform. It offers personal lending and wealth management solutions. The company was founded in August 2005 and is headquartered in Shanghai, China.

Lufax Holding Ltd - ADR

Lufax is drawing attention around its 1-for-10 ADS reverse split and Q3 results, following a preliminary loss warning citing higher credit impairments and taxes. Traders are divided between concerns about continued selling and hopes that much of the hit is one-off; dividend, buyback, and take-private speculation also remains unconfirmed.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibres quarterly results beat expectations on revenue and earnings, but shares sold off as investors focused on declining profitability and margin pressure from heavy spending on logistics, shipping and credit expansion. Bulls see the spending as investment in long-term growth, while bears question when margins will recover and criticize the stocks weak price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?

J&J stock reclaims its 50-day SMA, but falling earnings estimates, a premium valuation and MedTech weakness raise questions about its near-term outlook.

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Market Updates News Commentary- Two unrelated...

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today

Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.28% on an annualized basis producing an average annual return of 19.88%. Currently, Protagonist Therapeutics has a marketread more...

J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?

JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead

JNJ's pipeline remains a key growth driver, with new launches, late-stage data and approvals supporting momentum through the rest of 2026 and beyond.

J&J's New Growth Powerhouses: Immunology and Neuroscience

J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.&nbsp;</li><li>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises.</li><li>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde.</li></ul><p>Wall Street on Wednesday reiterated confidence in Protagonist Therapeutics (PTGX) after John and Johnson received U.S. Food and Drug Administration’s approval for Icotyde for the treatment of moderate-to-severe plaque psoriasis.</p><p>The FDA approved the drug in adults and pediatric patients 12 years of age and older. The approval was based on four late-stage studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients.</p><h2 class="st-heading-2">Protagonist’s Role In Icotyde</h2><p>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.</p><p>FDA approval of Icotyde triggers a $50 million milestone payment to Protagonist, the company said, while adding that it is eligible eligible to receive up to $580 million in potential additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales.</p><h2 class="st-heading-2">Analyst Take</h2><p>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises. Johnson &amp; Johnson is committed to building Icotyde into a blockbuster, which should create "significant value" for Protagonist Therapeutics (PTGX), the analyst told investors in a research note.</p><p>H.C. Wainwright believes Icotyde is positioned to "transform the plaque psoriasis landscape with a differentiated label that highlights its superior efficacy and safety profile." The firm reiterated a ‘Buy’ rating on Protagonist with a $117 price target.</p><p>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde. The approval transitions Protagonist into a company with royalty-bearing commercial exposure, while retaining upside from lifecycle expansion and the broader pipeline, the firm said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PTGX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/PTGX">PTGX stock</a> has gained 78% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-chair-powell-says-iran-war-will-spike-inflation-in-the-near-term-but-too-soon-to-assess-impact/cZ37Nb9RIW5">Fed Chair Powell Says Iran War Will Spike Inflation In The Near Term, But Too Soon To Assess Impact</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 

Johnson & Johnson

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$PTGX Latest analyst update, Oct 21, 2026: TD Cowen kept Buy and raised its price target on Protagonist Therapeutics to 160 USD from 155 USD. Third-party analyst opinion. 
 
More details in our $PTGX stock hub.  
Not investment advice.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTGX Protagonist Therapeutics Inc

Fundamentals

Latest PTGX News